Press releases
GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Commission (EC) has granted marketing authorisation for Benlysta®(belimumab) 10mg/kg as an add-on therapy in adult patients with active autoantibody-positive systemic lupus erythematosus (SLE), with a high degree of disease activity (e.g. positive anti-dsDNA and low complement), despite standard therapy1.
EU and US Regulatory Update - Votrient® (pazopanib)
GlaxoSmithKline (GSK) announced today that it has submitted a variation to the Marketing Authorisation Application to the European Medicines Agency for Votrient (pazopanib) for the treatment of patients with advanced soft tissue sarcoma who have received prior chemotherapy, or for patients who are unsuited for such therapy.
London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency to help fight against abuse of drugs in sport
London 2012 partner GlaxoSmithKline (GSK) today signed a long-term agreement with the World Anti-Doping Agency (WADA) that will help the agency create early detection methods for medicines that have performance-enhancing potential in sport.
GlaxoSmithKline receives new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan
– GSK’s rotavirus vaccine approved for use in babies for the prevention of rotavirus gastroenteritis – Lamotrigine becomes the first treatment to be approved in Japan for adult bipolar disorder
GSK welcomes external scientists to diseases of the developing world research campus
GSK will provide support, expertise and facilities as part of our open innovation strategy to spur global collaboration in research
GSK statement on University of East Anglia study examining health impacts of anticholinergic medicines for over 65s
Research led by the University of East Anglia has been published in the Journal of the American Geriatrics Society i examining the long term health impacts of anticholinergic medicines, a wide-ranging group of drugs frequently taken by older people.
GSK statement on agreements with State Attorneys General on former Cidra manufacturing facility
GlaxoSmithKline (GSK) has agreed to pay $40.75 million, which will be divided among 37 states and the District of Columbia, as part of an agreement reached related to events during the early 2000s at its former manufacturing facility in Cidra, Puerto Rico.
GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China
GlaxoSmithKline (GSK) announced today that it has entered into an agreement to acquire the remaining 51% equity interest of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd (Neptunus) in the joint venture (JV) company, Shenzhen GSK-Neptunus Biologicals Co. Ltd. (GSKNB), for a total cash consideration of£24 million (US$39 million). After approval of this agreement by the Peoples Republic of China’s authorities, GSK will become the sole owner of GSKNB.
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)
GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga™ (ezogabine) Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.
Millions of children in the world’s poorest countries could receive vaccination against rotavirus diarrhoeal disease under new offer made by GSK to the GAVI Alliance
GSK today announced that it has made a new offer to supply its rotavirus vaccine, Rotarix, to the GAVI Alliance at $2.50 per dose, a small fraction of developed world prices.
